| Literature DB >> 28203289 |
Hanem El-Sharkawy1,2, Amin Tahoun1,2, Abd El-Galiel A El-Gohary2, Moshira El-Abasy2, Fares El-Khayat2, Trudi Gillespie3, Yukio Kitade1, Hafez M Hafez4, Heinrich Neubauer5, Hosny El-Adawy5,2.
Abstract
BACKGROUND: Salmonella is one of major causes of foodborne outbreaks globally. This study was conducted to estimate the prevalence, typing and antibiotic susceptibilities of Salmonella enterica serovars isolated from 41 broiler chicken farms located in Kafr El-Sheikh Province in Northern Egypt during 2014-2015. The clinical signs and mortalities were observed.Entities:
Keywords: Antimicrobial; Broiler; Epidemiology; Integron; Salmonella
Year: 2017 PMID: 28203289 PMCID: PMC5301364 DOI: 10.1186/s13099-017-0157-1
Source DB: PubMed Journal: Gut Pathog ISSN: 1757-4749 Impact factor: 4.181
Flock description, signs, mortalities and Salmonella isolation rate from broiler chicken farms in the Kafr El-Sheikh Province Northern Egypt
| Flock no. | No. of birds | Age/day | Clinical signs | Mortality, n (%) | Isolation results |
|---|---|---|---|---|---|
| 1 | 10,000 | 1 | Pasty diarrhea, blindness, lameness and high mortality | 850 (8.5) |
|
| 2 | 10,000 | 2 | Inappetence and respiratory manifestation | 110 (1.1) | Negative |
| 3 | 15,000 | 3 | Pasty diarrhea, conjunctivitis, lowering in body weight and high mortalities | 975 (6.5) |
|
| 4 | 15,000 | 4 | Inappetence, ruffling feather and nervous signs | 360 (2.4) | Negative |
| 5 | 25,000 | 5 | Lowering body rate and respiratory signs | 550 (2.2) | Negative |
| 6 | 2000 | 7 | Pasty diarrhea, loss of appetite, ruffling feather and high mortalities | 190 (9.5) |
|
| 7 | 5000 | 7 | Decreased body weight, diarrhea, dehydration and high mortalities | 415 (8.3) |
|
| 8 | 20,000 | 4 | Decreased body weight | 500 (2.5) | Negative |
| 9 | 10,000 | 6 | Whitish diarrhea, high mortalities, and decreased body weight | 1160 (11.6) |
|
| 10 | 12,000 | 7 | Inappetence, diarrhea and lowering body weight | 540 (4.5) | Negative |
| 11 | 25,000 | 7 | Inability to move and nervous signs | 850 (3.4) | Negative |
| 12 | 30,000 | 5 | Diarrhea, drop in feed intake and high mortalities | 2610 (8.7) |
|
| 13 | 5000 | 4 | Respiratory signs and decreased body weight | 225 (4.5) | Negative |
| 14 | 30,000 | 3 | Inappetence, lowering growth rate | 840 (2.8) | Negative |
| 15 | 15,000 | 6 | Whitish diarrhea, conjunctivitis and decreased body weight | 945 (6.3) |
|
| 16 | 10,000 | 4 | Diarrhea and decrease in body weight and respiratory signs | 350 (3.5) | Negative |
| 17 | 10,000 | 5 | Inappetence, mortalities, lameness and diarrhea | 550 (5.5) |
|
| 18 | 20,000 | 6 | Decreased body weight and respiratory signs | 640 (3.2) | Negative |
| 19 | 12,000 | 5 | Diarrhea, blindness and high mortality | 648 (5.4) |
|
| 20 | 10,000 | 5 | Respiratory and nervous signs | 420 (4.2) | Negative |
| 21 | 15,000 | 33 | Inappetence and respiratory manifestation | 375 (2.5) |
|
| 22 | 20,000 | 32 | Decreased body weight | 280 (1.4) | Negative |
| 23 | 30,000 | 33 | Mortalities | 660 (2.2) | Negative |
| 24 | 25,000 | 29 | Nervous signs | 625 (2.5) | Negative |
| 25 | 15,000 | 34 | Decreased body weight | 345 (2.3) |
|
| 26 | 20,000 | 29 | Decreased body weight | 460 (2.3) | Negative |
| 27 | 30,000 | 30 | Decreased body weight | 780 (2.6) | Negative |
| 28 | 10,000 | 31 | Respiratory signs and high mortality | 330 (3.3) |
|
| 29 | 5000 | 28 | Respiratory signs and mortalities | 165 (3.3) | Negative |
| 30 | 15,000 | 33 | Inappetence and mortalities | 480 (3.2) | Negative |
| 31 | 20,000 | 33 | Respiratory signs and high mortality | 600 (3.0) |
|
| 32 | 20,000 | 32 | Inappetence and respiratory manifestation | 700 (3.5) |
|
| 33 | 10,000 | 28 | Mortalities | 200 (2.0) | Negative |
| 34 | 20,000 | 29 | Mortalities | 480 (2.4) | Non typable |
| 35 | 10,000 | 33 | Respiratory signs and mortalities | 290 (2.9) |
|
| 36 | 5000 | 33 | Lower body weight and respiratory signs | 135 (2.7) | Negative |
| 37 | 15,000 | 32 | Nervous signs | 345 (2.3) | Negative |
| 38 | 20,000 | 33 | Inappetence and mortalities | 540 (2.7) | Negative |
| 39 | 10,000 | 31 | Respiratory signs and mortalities | 320 (3.2) |
|
| 40 | 5000 | 29 | Nervous manifestations and inappetence | 140 (2.8) | Negative |
| 41 | 25,000 | 35 | Opisthosomas and ruffled feather | 825 (3.3) | Negative |
Primer sequences and their corresponding genes used for the detection of S. enterica serovar Enteritidis and S. enterica serovar Typhimurium
| Gene | Oligonucleotide sequence (5′–3′) | Annealing (°C) | Amplicon size (bp) | Reference |
|---|---|---|---|---|
|
| GCT GCG CGC GAA CGG CGA AG | 62 | 389 | [ |
|
| TCC CGG CAG AGT TCC CAT T | |||
|
| TGTGTTTTATCTGATGCAAGAGG | 58 | 293 | [ |
|
| CGTTCTTCTGGTACTTACGATGAC | |||
|
| GCGAATATCATTCAGGATAAC | 58 | 450 | [ |
|
| GCATGTCATACCGTTGTGGA | |||
|
| GCTGACTCACACAGGAAATCG | 58 | 350 | [ |
|
| TCTGATAAGACTGGGTTTCACT | |||
|
| GCC GTA CAC GAG CTT ATA GA | 55 | 250 | [ |
|
| ACC TAC AGG GGC ACA ATA AC | |||
|
| CCCCGCTTACAGGTGGACTAC | 62 | 433 | [ |
|
| AGCGGGTTTTCGGTGGTTGT | |||
|
| ACA CAC TTT CCA CGA GGA AGC G | 55 | 398 | [ |
|
| GGA TGC CTT CTG ATG TTG ACT GG | |||
|
| TTGTTCACTTTTTACCCCTGA A | 55 | 401 | [ |
|
| CCCTGACAGCCGTTAGATATT |
Breakpoint values of each antimicrobial agent and phenotypic antimicrobial susceptibility profiles of 67 tested isolates used in this study according to EUCAST, 2015
| Antimicrobial agents | Conc. (µg) | Diameter of inhibition zone (mm) |
|
| Non typable (3) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R | I | S | R | I | S | R | I | S | R | I | S | ||
| Ampicillin | 10 | ≤13 | 14–16 | ≥17 | 58 (100%) | – | – | – | – | 6 (100%) | 3 (100%) | – | – |
| Chloramphenicol | 30 | ≤12 | 13–17 | ≥18 | 58 (100%) | – | – | – | – | 6 (100%) | 3 (100%) | – | – |
| Gentamicin | 10 | ≤12 | 13–15 | ≥16 | – | – | 58 (100%) | – | – | 6 (100%) | – | 3 (100%) | – |
| Streptomycin | 25 | ≤11 | 12–14 | ≥15 | – | 6 (10.3%) | 52 (89.7%) | – | – | 6 (100%) | – | 3 (100%) | – |
| Tetracycline | 30 | ≤14 | 15–18 | ≥19 | 58 (100%) | – | – | – | – | 6 (100%) | 3 (100%) | – | – |
| Trimethoprim/sulphamethoxazole | 25 | ≤10 | 11–15 | ≥16 | 3 (5.2%) | – | 55 (94.8%) | – | – | 6 (100%) | – | 3 (100%) | – |
S sensitive, I intermediate, R resistance
Primer sequences and their corresponding genes used for detection of antimicrobial resistant genes for S. enterica serovars
| Gene | Primer | Nucleotide sequence (5–3) | Annealing (°C) | Amplicon size (bp) | Reference |
|---|---|---|---|---|---|
|
| F | TATCAGAGGTAGTTGGCGTCAT | 54 | 484 | [ |
| R | GTTCCATAGCGTTAAGGTTTCATT | ||||
|
| F | TGTTGGTTACTGTGGCCGTA | 62 | 622 | [ |
| R | GATCTCGCCTTTCACAAAGC | ||||
|
| F | GAGCGAAATCTGCCGCTCTGG | 61 | 319 | [ |
| R | CTGTTACAACGGACTGGCCGC | ||||
|
| F | GGCGCGATCAACGAATTTATCCGA | 58 | 488 | [ |
| R | CCATTCGATGCCGAAGGAAACGAT | ||||
|
| F | CATTTCCGTGTCGCCCTTAT | 55 | 793 | [ |
| R | TCCATAGTTGCCTGACTCCC | ||||
|
| F | CTT GTC GCC TTG CGT ATA AT | 53 | 508 | [ |
| R | ATC CCA ATG GCA TCG TAA AG | ||||
|
| F | CCGGATTGACCTGAATACCT | 56 | 572 | [ |
| R | TCACATACTGCATGATGAAC | ||||
|
| F | GTGAAACTATCACTAATGGTAGCT | 54 | 470 | [ |
| R | ACCCTTTTGCCAGATTTGGTAACT | ||||
|
| F | AACCCGCCCTCTGGATCAAGTCAA | 60 | 548 | [ |
| R | CAAATCACGGGCCACGCTGTATC | ||||
|
| F | AGCAGAGCGCGCCTTCGCTC | 59 | 684 | [ |
| R | CCAAAGCCCACTTCACCGAC | ||||
|
| F | ATCGTCAAGGGATTGAAACC | 49 | 509 | [ |
| R | GGATCGTAGAACATATTGGC | ||||
|
| F | TCACCGAGGACTCCTTCTTC | 60 | 316 | [ |
| R | AATATCGGGATAGAGCGCAG | ||||
|
| F | CGGTCCGGCATCCAGCAATCC | 64 | 441 | [ |
| R | CGAGAGCCACGACCGCGCC | ||||
|
| F | GAGCAAGATTTTTGGAATCG | 51 | 799 | [ |
| R | CATCTGCAGCTAACCTAGGGCTTGGA | ||||
|
| F | GCTACATCCTGCTTGCCTTC | 55 | 210 | [ |
| R | CATAGATCGCCGTGAAGAGG | ||||
|
| F | TTGGTTAGGGGCAAGTTTTG | 53 | 659 | [ |
| R | GTAATGGGCCAATAACACCG | ||||
|
| F | CTTGAGAGCCTTCAACCCAG | 56 | 418 | [ |
| R | ATGGTCGTCATCTACCTGCC | ||||
| intI | F | 5′GGCATCCAAGCAGCAAGC-3′ | 55 | 2000 | [ |
| R | AAGCAGACTTGACCTGAT |
The rate of S. enterica serovars isolation from tissue organs collected from 41 broiler chicken flocks in Kafr El-Sheikh Province in Northern Egypt
| Organs | Liver | Intestine | Gallbladder | Total | |
|---|---|---|---|---|---|
| No. of collected samples | 205 | 205 | 205 | 615 | |
| No. of isolates | |||||
| | 2 (0.98%) | 1 (0.49%) | 3 (1.46%) | 6 (0.98%) | |
|
| 20 (9.76%) | 8 (3.9%) | 30 (14.63%) | 58 (9.43%) | |
| Un-typable | 0 | 3 (1.46%) | 0 | 3 (0.49%) | |
| Total | 22 (10.74%) | 12 (5.85%) | 33 (16.09%) | 67 (10.9%) | |
Fig. 1a Molecular biological identification of virulent gene associated with of S. enterica serovars Enteritidis and S. enterica serovar Typhimurium. Lane M, 100 bp DNA ladder. PCR amplification of invA, Typh, fliC, sdfI, sdfII, sdfIII and sefA with expected amplicon size 389, 401, 433, ~293, ~450, ~350 and 250 bp, respectively. b Agarose gel electrophoresis of PCR amplifications of sopE gene in S. enterica serovars Enteritidis and S. enterica serovars Typhimurium. Lane M, 100 bp DNA ladder. Lanes 1–2 and 5–8 were positive for the sopE with amplicon size 398 bp. c Molecular biological detection of antimicrobial resistant associated genes in S. enterica serovar Enteritidis and S. enterica serovar Typhimurium isolates. The amplified genes were intI integrons, BlaTEM, aadA2, floR, cat1, sul1, and tetA genes with amplicon size 2000, 793, 622, 548, 508, 316 and 210 bp, respectively. Lane M, 100 bp DNA ladder
Prevalence of antibiotic resistant associated genes detected in S. enterica serovars
| Resistance markers | Prevalence of resistance genes in screened | Antimicrobial agent | ||
|---|---|---|---|---|
|
|
| Non-typable | ||
|
| 38 | 0 | 0 | Ampicillin |
|
| 49 | 3 | 3 | Tetracycline |
|
| 0 | 0 | 0 | Tetracycline |
|
| 56 | 2 | 0 | Tetracycline |
|
| 33 | 1 | 0 | Sulphamethoxazole |
|
| 0 | 0 | 0 | Sulphamethoxazole |
|
| 57 | 0 | 0 | Sulphamethoxazole |
|
| 24 | 3 | 0 | Streptomycin |
|
| 55 | 2 | 0 | Streptomycin |
|
| 36 | 2 | 0 | Streptomycin |
|
| 0 | 0 | 0 | Streptomycin |
|
| 0 | 0 | 0 | Gentamycin |
|
| 0 | 0 | 0 | Gentamycin |
|
| 58 | 2 | 1 | Chloramphenicol |
|
| 0 | 0 | 0 | Chloramphenicol |
|
| 46 | 1 | 0 | Chloramphenicol |
|
| 0 | 0 | 0 | Trimethoprim |
|
| 3 | 0 | 0 | Class I integron |